Glenmark Pharma Says U.S. FDA Inspection At Co' Facility At Monroe

ReutersJun 18, 2025 5:43 AM

June 18 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

U.S. FDA INSPECTION AT THE COMPANY'S FACILITY AT MONROE, NORTH CAROLINA, USA
COMPANY WAS ISSUED A FORM 483 WITH FIVE OBSERVATIONS BY USFDA
OBSERVATIONS ARE PROCEDURAL IN NATURE
THERE WAS NO OBSERVATION RELATED TO DATA INTEGRITY REPORTED

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

Robinhood’s earnings miss triggered a sharp decline in its stock price and intensified market concerns regarding Coinbase.

Today’s Market Recap: SoftBank and Oracle Retreat on OpenAI Misses Amid NVIDIA’s ‘Nano’ Efficiency Breakthrough

OpenAI's missed targets trigger a retreat in SoftBank and Oracle, while NVIDIA unveils its high-efficiency 'Nano' AI model. Plus, updates on the Strait of Hormuz tensions, the Fed's stagflation debate, and BoJ's hawkish hold.

MSTR Stock Price Prediction 2026-2030: Is Strategy the Ultimate Bitcoin Leveraged Play?

trategy Inc. has evolved from a nascent software company into a complex financial engine. Whether you are watching the MSTR stock price today for a day trade or evaluating it for a decade-long hold, the company represents the premier equity vehicle for the digital age.

Deep Analysis 48 Hours Before Microsoft Earnings: OpenAI Agreement Restructuring Implemented, Three Variables of Azure, Copilot, and Capital Expenditure Determine MSFT Valuation Recovery Path

Microsoft released its FY26 Q3 earnings on April 29. This article provides an in-depth analysis of the impact of the OpenAI agreement restructuring, examining three key metrics—Azure growth, a 3.3% Copilot penetration rate, and $110 billion in capital expenditure—to determine whether MSFT’s forward P/E of 22x offers a long-term positioning opportunity.

Microsoft 2026 Q3 Earnings Preview: Can Azure’s Growth Momentum Keep Up With Massive AI Capital Spending?

TradingKey - Microsoft (MSFT) is scheduled to release its Q3 FY2026 earnings report after the market close on April 29, ET. As one of the most proactive tech giants in advancing global AI strategies, this report is regarded as a key indicator for evaluating the large-scale monetization of AI technology and the growth resilience of its cloud business.

Featured Tools